Sec. 2. (a) Subject to subsection (d), every infant shall be given examinations at the earliest feasible time for the detection of the following disorders:
(1) Phenylketonuria.
(2) Hypothyroidism.
(3) Hemoglobinopathies, including sickle cell anemia.
(4) Galactosemia.
(5) Maple Syrup urine disease.
(6) Homocystinuria.
(7) Inborn errors of metabolism that result in an intellectual disability and that are designated by the state department.
(8) Congenital adrenal hyperplasia.
(9) Biotinidase deficiency.
(10) Disorders detected by tandem mass spectrometry or other technologies with the same or greater detection capabilities as tandem mass spectrometry, if the state department determines that the technology is available for use by a designated laboratory under section 7 of this chapter.
(11) Spinal muscular atrophy.
(12) Severe combined immunodeficiency.
(13) Beginning July 1, 2020, Krabbe disease.
(14) Beginning July 1, 2020, Pompe disease.
(15) Beginning July 1, 2020, Hurler syndrome (MPS1).
(16) Adrenoleukodystrophy (ALD).
(b) Subject to subsection (d), every infant shall be given a physiologic hearing screening examination at the earliest feasible time for the detection of hearing impairments.
(c) Subject to subsection (d), every infant shall be given a pulse oximetry screening examination in accordance with rules adopted by the department for the detection of low oxygen levels. Section 10(a)(2) of this chapter does not apply to this subsection.
(d) If a parent of an infant objects in writing, for reasons pertaining to religious beliefs only, the infant is exempt from the examinations required by this chapter.
[Pre-1993 Recodification Citation: 16-8-6-1.]
As added by P.L.2-1993, SEC.24. Amended by P.L.91-1999, SEC.2; P.L.149-2001, SEC.3; P.L.229-2011, SEC.165; P.L.117-2015, SEC.34; P.L.17-2018, SEC.1; P.L.1-2019, SEC.1; P.L.19-2020, SEC.1.